Neuronetics, Inc. provided earnings guidance for the second quarter of fiscal year 2024. For the quarter, the company expects total worldwide revenue between $18.0 million and $19.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 USD | -2.40% | -13.98% | -30.00% |
05-15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
05-14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.00% | 61.2M | |
+6.88% | 217B | |
+10.63% | 190B | |
+18.16% | 141B | |
+29.70% | 110B | |
+2.09% | 64.8B | |
+14.14% | 52.44B | |
+3.01% | 49.94B | |
+4.64% | 42.63B | |
+1.45% | 35.81B |
- Stock Market
- Equities
- STIM Stock
- News Neuronetics, Inc.
- Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024